Next, we blocked the EGFR using the anti-cancer compound, Gefitinib – a small-molecule inhibitor of the EGFR.25, 26 As shown in Figures 6e and f, Gefitinib significantly diminished PRM-mediated cytoprotection against etoposide exposure in both mouse neurons and human U937 monocytes. This evidence concerns the gene EGFR and cancer.